BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25378588)

  • 1. Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing.
    Shah A; Miller CJ; Nast CC; Adams MD; Truitt B; Tayek JA; Tong L; Mehtani P; Monteon F; Sedor JR; Clinkenbeard EL; White K; Mehrotra R; LaPage J; Dickson P; Adler SG; Iyengar SK
    Nephrol Dial Transplant; 2014 Dec; 29(12):2235-43. PubMed ID: 25378588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.
    Ramnitz MS; Gourh P; Goldbach-Mansky R; Wodajo F; Ichikawa S; Econs MJ; White KE; Molinolo A; Chen MY; Heller T; Del Rivero J; Seo-Mayer P; Arabshahi B; Jackson MB; Hatab S; McCarthy E; Guthrie LC; Brillante BA; Gafni RI; Collins MT
    J Bone Miner Res; 2016 Oct; 31(10):1845-1854. PubMed ID: 27164190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation.
    Goldenstein PT; Neves PD; Balbo BE; Elias RM; Pereira AC; Onuchic LF; Jüppner H; Jorgetti V; Abensur H; Moysés RM
    Am J Kidney Dis; 2018 Sep; 72(3):457-461. PubMed ID: 29548779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?
    Claramunt-Taberner D; Bertholet-Thomas A; Carlier MC; Dijoud F; Chotel F; Silve C; Bacchetta J
    Pediatr Nephrol; 2018 Jul; 33(7):1263-1267. PubMed ID: 29594503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.
    Chakhtoura M; Ramnitz MS; Khoury N; Nemer G; Shabb N; Abchee A; Berberi A; Hourani M; Collins M; Ichikawa S; El Hajj Fuleihan G
    Osteoporos Int; 2018 Sep; 29(9):1987-2009. PubMed ID: 29923062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
    Rafaelsen S; Johansson S; Ræder H; Bjerknes R
    BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF23-S129F mutant bypasses ER/Golgi to the circulation of hyperphosphatemic familial tumoral calcinosis patients.
    Shawar SM; Ramadan AR; Ali BR; Alghamdi MA; John A; Hudaib FM
    Bone; 2016 Dec; 93():187-195. PubMed ID: 26620085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel
    Zuo Q; Yang W; Liu B; Yan D; Wang Z; Wang H; Deng W; Cao X; Yang J
    Front Endocrinol (Lausanne); 2022; 13():1008800. PubMed ID: 36213261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperphosphataemic familial tumoral calcinosis: case report of a rare and challenging disease.
    Guerra MG; Videira T; de Fonseca D; Vieira R; Dos Santos J; Pinto S
    Scand J Rheumatol; 2020 Jan; 49(1):80-81. PubMed ID: 31213107
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
    Folsom LJ; Imel EA
    Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
    Dumitrescu CE; Kelly MH; Khosravi A; Hart TC; Brahim J; White KE; Farrow EG; Nathan MH; Murphey MD; Collins MT
    Osteoporos Int; 2009 Jul; 20(7):1273-8. PubMed ID: 18982401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis.
    Masi L; Gozzini A; Franchi A; Campanacci D; Amedei A; Falchetti A; Franceschelli F; Marcucci G; Tanini A; Capanna R; Brandi ML
    J Bone Joint Surg Am; 2009 May; 91(5):1190-8. PubMed ID: 19411468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
    Ichikawa S; Guigonis V; Imel EA; Courouble M; Heissat S; Henley JD; Sorenson AH; Petit B; Lienhardt A; Econs MJ
    J Clin Endocrinol Metab; 2007 May; 92(5):1943-7. PubMed ID: 17311862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective O-glycosylation of novel FGF23 mutations in a Chinese family with hyperphosphatemic familial tumoral calcinosis.
    Liu C; Pang Q; Jiang Y; Xia Y; Fang L; Wang O; Li M; Xing X; Gong Y; Xia W
    Bone; 2020 Aug; 137():115401. PubMed ID: 32360901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.
    Araya K; Fukumoto S; Backenroth R; Takeuchi Y; Nakayama K; Ito N; Yoshii N; Yamazaki Y; Yamashita T; Silver J; Igarashi T; Fujita T
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5523-7. PubMed ID: 16030159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies.
    Roberts MS; Burbelo PD; Egli-Spichtig D; Perwad F; Romero CJ; Ichikawa S; Farrow E; Econs MJ; Guthrie LC; Collins MT; Gafni RI
    J Clin Invest; 2018 Dec; 128(12):5368-5373. PubMed ID: 30226830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Regulation of mineral metabolism and mineralization by FGF23].
    Fukumoto S
    Clin Calcium; 2015 May; 25(5):687-91. PubMed ID: 25926572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.
    Larsson T; Yu X; Davis SI; Draman MS; Mooney SD; Cullen MJ; White KE
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2424-7. PubMed ID: 15687325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC).
    Vieira AR; Lee M; Vairo F; Loguercio Leite JC; Munerato MC; Visioli F; D'Ávila SR; Wang SK; Choi M; Simmer JP; Hu JC
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Dec; 120(6):e235-9. PubMed ID: 26337219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in
    Kışla Ekinci RM; Gürbüz F; Balcı S; Bişgin A; Taştan M; Yüksel B; Yılmaz M
    J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):94-99. PubMed ID: 30015621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.